

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 March 2002 (07.03.2002)

PCT

(10) International Publication Number
WO 02/18374 A1

(51) International Patent Classification⁷: **C07D 405/12**,
A61K 31/505, A61P 29/00

(GB). PEGG, Neil, Anthony [GB/GB]; c/o GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB).

(21) International Application Number: PCT/GB01/03935

(74) Agent: REEVES, Julie, Frances; GlaxoSmithKline, Corporate Intellectual Property (CN9.25.1), 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(22) International Filing Date: 31 August 2001 (31.08.2001)

(25) Filing Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(26) Publication Language: English

(30) Priority Data:
0021494.0 1 September 2000 (01.09.2000) GB

(71) Applicant (*for all designated States except US*): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **CARTER, Malcolm, Clive** [GB/GB]; c/o GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). **NAYLOR, Alan** [GB/GB]; c/o GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). **PASS, Martin** [GB/GB]; c/o GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). **PAYNE, Jeremy, John** [GB/GB]; c/o GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY

Published:


— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/18374 A1

(54) Title: SUBSTITUTED PYRIMIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS



(I)


(57) Abstract: A compound of formula (I) and pharmaceutically acceptable derivatives thereof, in which R¹ is H or C₁₋₆alkyl; R² is R³ is C₁₋₆alkyl or NH₂. Compounds of formula (I) are potent and selective inhibitors of COX-2 and are of use in the treatment of the pain, fever, inflammation of a variety of conditions and diseases.

SUBSTITUTED PYRIMIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS

This invention relates to pyrimidine derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine.

5 The enzyme cyclooxygenase (COX) has recently been discovered to exist in two isoforms, COX-1 and COX-2. COX-1 corresponds to the originally identified constitutive enzyme while COX-2 is rapidly and readily inducible by a number of agents including mitogens, endotoxin, hormones, cytokines and growth factors. Prostaglandins generated by the action of COX have both physiological and pathological roles. It is generally believed that COX-1 is largely responsible for the important physiological functions such as maintenance of gastrointestinal integrity and renal blood flow. In contrast the inducible form, COX-2, is believed to be largely responsible for the pathological effects of prostaglandins where rapid induction of the enzyme occurs in response to such agents as inflammatory agents, hormones, growth factors and cytokines. A selective inhibitor of COX-2 would therefore have anti-inflammatory, anti-pyretic and analgesic properties, without the potential side effects associated with inhibition of COX-1. We have now found a novel group of compounds which are both potent and selective inhibitors of COX-2.


20 The invention thus provides the compounds of formula (I)



and pharmaceutically acceptable derivatives thereof, in which:

R¹ is H or C₁₋₆alkyl;

R² is



) defines the point of attachment of the ring; and

R³ is C₁₋₆alkyl or NH₂.

5 By pharmaceutically acceptable derivative is meant any pharmaceutically acceptable salt, solvate, ester or amide, or salt or solvate of such ester or amide, of the compounds of formula (I), or any other compound which upon administration to the recipient is capable of providing (directly or indirectly) a compound of formula (I) or an active metabolite or residue thereof.

10 It will be appreciated by those skilled in the art that the compounds of formula (I) may be modified to provide pharmaceutically acceptable derivatives thereof at any of the functional groups in the compounds. Of particular interest as such derivatives are compounds modified at the benzenesulphonamide function to provide metabolically labile benzenesulphonamides. Acylated benzenesulphonamide derivatives are of especial interest.

15 It will be appreciated by those skilled in the art that the pharmaceutically acceptable derivatives of the compounds of formula (I) may be derivatised at more than one position.

20 It will be further appreciated by those skilled in the art that benzenesulphonamide derivatives of formula (I) may be useful as intermediates in the preparation of compounds of formula (I), or as pharmaceutically acceptable derivatives of formula (I), or both.

25 It will be appreciated that, for pharmaceutical use, the salts referred to above will be the physiologically acceptable salts, but other salts may find use, for example in the preparation of compounds of formula (I) and the physiologically acceptable salts thereof.

Suitable pharmaceutically acceptable salts include: acid addition salts formed with inorganic or organic acids, preferably inorganic acids, e.g. hydrochlorides,

hydrobromides and sulphates; and alkali metal salts, formed from addition of alkali metal bases, such as alkali metal hydroxides, e.g. sodium salts.

The term halogen is used to represent fluorine, chlorine, bromine or iodine.


5 The term 'alkyl' as a group or part of a group means a straight or branched chain alkyl group, for example a methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl or t-butyl group.

10 It is to be understood that the present invention encompasses all isomers of the compounds of formula (I) and their pharmaceutically acceptable derivatives, including all geometric, tautomeric and optical forms, and mixtures thereof (e.g. racemic mixtures). In particular, when the ring R^2 lacks a plane of symmetry the compounds of formula (I) contain a chiral centre, as indicated therein by the asterisk *.

In one aspect of the invention R^1 is H.


In another aspect of the invention R^1 is C_{1-2} alkyl.

15 In another aspect of the invention R^2 is



In another aspect of the invention R^3 is C_{1-6} alkyl, such as C_{1-3} alkyl (e.g. methyl).

Within the invention there is provided one group of compounds of formula (I) wherein: R^1 is H; R^2 is




20

and R^3 is C_{1-6} alkyl, such as C_{1-3} alkyl (e.g. methyl).

Within the invention there is provided another group of compounds of formula (I) wherein: R^1 is C_{1-2} alkyl; R^2 is

4



and R^3 is C_{1-6} alkyl, such as C_{1-3} alkyl (e.g. methyl).

In another aspect the invention provides the following compounds:

4-[4-(methylsulfonyl)phenyl]-N-tetrahydro-2H-pyran-4-yl-6-

5 (trifluoromethyl)pyrimidin-2-amine;

4-[4-(methylsulfonyl)phenyl]-N-methyl-N-tetrahydro-2H-pyran-4-yl-6-

(trifluoromethyl)pyrimidin-2-amine;

4-[4-(methylsulfonyl)phenyl]-N-ethyl-N-tetrahydro-2H-pyran-4-yl-6-

(trifluoromethyl)pyrimidin-2-amine;

10 and pharmaceutically acceptable derivatives thereof.

Since the compounds of the present invention, in particular compounds of formula (I), are intended for use in pharmaceutical compositions, it will be understood that they are each provided in substantially pure form, for example at
 15 least 50% pure, more suitably at least 75% pure and preferably at least 95% pure (% are on a wt/wt basis). Impure preparations of the compounds of formula (I) may be used for preparing the more pure forms used in the pharmaceutical compositions. Although the purity of intermediate compounds of the present invention is less critical, it will be readily understood that the substantially pure form is preferred as for the compounds of formula (I). Preferably, whenever
 20 possible, the compounds of the present invention are obtained in crystalline form.

When some of the compounds of this invention are allowed to crystallise or are
 25 recrystallised from organic solvents, solvent of crystallisation may be present in the crystalline product. This invention includes within its scope such solvates. Similarly, some of the compounds of this invention may be crystallised or recrystallised from solvents containing water. In such cases water of hydration may be formed. This invention includes within its scope stoichiometric hydrates
 30 as well as compounds containing variable amounts of water that may be produced by processes such as lyophilisation. In addition, different crystallisation conditions may lead to the formation of different polymorphic

forms of crystalline products. This invention includes within its scope all polymorphic forms of the compounds of formula (I).

Compounds of the invention are potent and selective inhibitors of COX-2. This activity is illustrated by their ability to selectively inhibit COX-2 over COX-1.

5 In view of their selective COX-2 inhibitory activity, the compounds of the present invention are of interest for use in human and veterinary medicine, particularly in the treatment of the pain (both chronic and acute), fever and inflammation of a variety of conditions and diseases mediated by selective inhibition of COX-2. Such conditions and diseases are well known in the art and include rheumatic
10 fever; symptoms associated with influenza or other viral infections, such as the common cold; lower back and neck pain; headache; toothache; sprains and strains; myositis; neuropathic pain (e.g. neuralgia, such as post herpetic neuralgia, trigeminal neuralgia and sympathetically maintained pain); synovitis; arthritis, including rheumatoid arthritis; degenerative joint diseases, including
15 osteoarthritis; gout and ankylosing spondylitis; tendinitis; bursitis; skin related conditions, such as psoriasis, eczema, burns and dermatitis; injuries, such as sports injuries and those arising from surgical and dental procedures.

The compounds of the invention are also useful for the treatment of other conditions mediated by selective inhibition of COX-2.

20 For example, the compounds of the invention inhibit cellular and neoplastic transformation and metastatic tumour growth and hence are useful in the treatment of certain cancerous diseases, such as colonic cancer. The compounds of the invention are also useful in reducing the number of adenomatous colorectal polyps, and thus reduce the risk of developing colon
25 cancer. The compounds of the invention are also useful in the treatment of cancer associated with overexpression of HER-2/neu, in particular breast cancer.

Compounds of the invention also prevent neuronal injury by inhibiting the generation of neuronal free radicals (and hence oxidative stress) and therefore
30 are of use in the treatment of stroke; epilepsy; and epileptic seizures (including grand mal, petit mal, myoclonic epilepsy and partial seizures).

Compounds of the invention also inhibit prostanoid-induced smooth muscle contraction and hence are of use in the treatment of dysmenorrhoea and premature labour.

5 Compounds of the invention are also useful in the treatment of liver disease such as inflammatory liver disease, for example chronic viral hepatitis B, chronic viral hepatitis C, alcoholic liver injury, primary biliary cirrhosis, autoimmune hepatitis, nonalcoholic steatohepatitis and liver transplant rejection.

10 Compounds of the invention inhibit inflammatory processes and therefore are of use in the treatment of asthma, allergic rhinitis and respiratory distress syndrome; gastrointestinal conditions such as inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome and ulcerative colitis; and the inflammation in such diseases as vascular disease, migraine, periarteritis nodosa, thyroiditis, aplastic anaemia, Hodgkin's disease, sclerodoma, type I diabetes, myasthenia gravis, multiple sclerosis, sarcoidosis, nephrotic syndrome, 15 Bechet's syndrome, polymyositis, gingivitis, conjunctivitis and myocardial ischemia.

Compounds of the invention are also useful in the treatment of ophthalmic diseases such as retinitis, retinopathies, uveitis and of acute injury to the eye tissue.

20 Compounds of the invention are also useful for the treatment of cognitive disorders such as dementia, particularly degenerative dementia (including senile dementia, Alzheimer's disease, Pick's disease, Huntington's chorea, Parkinson's disease and Creutzfeldt-Jakob disease), and vascular dementia (including multi-infarct dementia), as well as dementia associated with intracranial space 25 occupying lesions, trauma, infections and related conditions (including HIV infection), metabolism, toxins, anoxia and vitamin deficiency; and mild cognitive impairment associated with ageing, particularly Age Associated Memory Impairment.

30 Compounds of the invention are also useful in the treatment of disorders ameliorated by a gastroprokinetic agent. Disorders ameliorated by gastroprokinetic agents include ileus, for example post-operative ileus and ileus during sepsis; gastroesophageal reflux disease (GORD, or its synonym GERD);

gastroparesis, such as diabetic gastroparesis; and other functional bowel disorders, such as non-ulcerative dyspepsia (NUD) and non-cardiac chest pain (NCCP).

5 According to a further aspect of the invention, we provide a compound of formula (I) or a pharmaceutically acceptable derivative thereof for use in human or veterinary medicine.

According to another aspect of the invention, we provide a compound of formula (I) or a pharmaceutically acceptable derivative thereof for use in the treatment of a condition which is mediated by selective inhibition of COX-2.

10 According to a further aspect of the invention, we provide a method of treating a human or animal subject suffering from a condition which is mediated by selective inhibition of COX-2 which comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative.

15 According to a further aspect of the invention, we provide a method of treating a human or animal subject suffering from an inflammatory disorder, which method comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

20 According to another aspect of the invention, we provide the use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof for the manufacture of a therapeutic agent for the treatment of a condition which is mediated by selective inhibition of COX-2.

25 According to another aspect of the invention, we provide the use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof for the manufacture of a therapeutic agent for the treatment of an inflammatory disorder.

It is to be understood that reference to treatment includes both treatment of established symptoms and prophylactic treatment, unless explicitly stated otherwise.

It will be appreciated that the compounds of the invention may advantageously be used in conjunction with one or more other therapeutic agents. Examples of suitable agents for adjunctive therapy include pain relievers such as a 5HT₁ agonist (e.g. sumatriptan), an adenosine A₁ agonist, an EP ligand (e.g. an EP₄ antagonist), a glycine antagonist, a sodium channel inhibitor (e.g. lamotrigine), a substance P antagonist (e.g. an NK₁ antagonist), cannabinoids, acetaminophen or phenacetin; a matrix metalloproteinase inhibitor; a nitric oxide synthase (NOS) inhibitor (e.g. an iNOS or an nNOS inhibitor); an inhibitor of the release, or action, of tumour necrosis factor α ; an antibody therapy (e.g. a monoclonal antibody therapy); a stimulant, including caffeine; an H₂-antagonist, such as ranitidine; a proton pump inhibitor, such as omeprazole; an antacid, such as aluminium or magnesium hydroxide; an antiflatulent, such as simethicone; a decongestant, such as phenylephrine, phenylpropanolamine, pseudoephedrine, oxymetazoline, epinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxyephedrine; an antitussive, such as codeine, hydrocodone, carmiphen, carbetapentane, or dexamethorphan; a diuretic; or a sedating or non-sedating antihistamine. It is to be understood that the present invention covers the use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof in combination with one or more other therapeutic agents.

Further examples of suitable agents for adjunctive therapy include a 5-lipoxygenase inhibitor; a leukotriene receptor antagonist; a DMARD (e.g. methotrexate); gabapentin and related compounds; a tricyclic antidepressant (e.g. amitriptyline); a neurone stabilising antiepileptic drug; a mono-aminergic uptake inhibitor (e.g. venlafaxine); an antiviral agent, such as a nucleoside inhibitor (e.g. lamivudine) or an immune system modulator (e.g. interferon); an opioid analgesic or a local anaesthetic.

The compounds of formula (I) and their pharmaceutically acceptable derivatives are conveniently administered in the form of pharmaceutical compositions. Thus, in another aspect of the invention, we provide a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof adapted for use in human or veterinary medicine. Such compositions may conveniently be presented for use in conventional manner in admixture with one or more physiologically acceptable carriers or excipients.

The compounds of formula (I) and their pharmaceutically acceptable derivatives may be formulated for administration in any suitable manner. They may, for example, be formulated for topical administration or administration by inhalation or, more preferably, for oral, transdermal or parenteral administration. The pharmaceutical composition may be in a form such that it can effect controlled release of the compounds of formula (I) and their pharmaceutically acceptable derivatives.

For oral administration, the pharmaceutical composition may take the form of, for example, tablets (including sub-lingual tablets), capsules, powders, solutions, syrups or suspensions prepared by conventional means with acceptable excipients.

For transdermal administration, the pharmaceutical composition may be given in the form of a transdermal patch, such as a transdermal iontophoretic patch.

For parenteral administration, the pharmaceutical composition may be given as an injection or a continuous infusion (e.g. intravenously, intravascularly or subcutaneously). The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. For administration by injection these may take the form of a unit dose presentation or as a multidose presentation preferably with an added preservative.

Alternatively for parenteral administration the active ingredient may be in powder form for reconstitution with a suitable vehicle.

The compounds of the invention may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

As stated above, the compounds of the invention may also be used in combination with other therapeutic agents. The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a

pharmaceutically acceptable derivative thereof together with a further therapeutic agent.

The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier or excipient comprise a further aspect of the invention. The individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.


When a compound of formula (I) or a pharmaceutically acceptable derivative thereof is used in combination with a second therapeutic agent active against the same disease state the dose of each compound may differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.

A proposed daily dosage of a compound of formula (I) for the treatment of man is 0.01mg/kg to 500mg/kg, such as 0.05mg/kg to 100mg/kg, e.g. 0.1mg/kg to 50mg/kg, which may be conveniently administered in 1 to 4 doses. The precise dose employed will depend on the age and condition of the patient and on the route of administration. Thus, for example, a daily dose of 0.25mg/kg to 10mg/kg may be suitable for systemic administration.

Compounds of formula (I) and pharmaceutically acceptable derivatives thereof may be prepared by any method known in the art for the preparation of compounds of analogous structure.

Compounds of formula (I) and pharmaceutically acceptable derivatives thereof may be prepared by a process which comprises:

(A), reacting an amine HNR^1R^2 of formula (II) or a protected derivative thereof with a compound of formula (III)



or a protected derivative thereof; or

(B), interconverting of a compound of formula (I) into another compound of formula (I); in particular, for a compound of formula (I) in which R^1 is H, alkylation thereof to give a compound of formula (I) in which R^1 is C_{1-6} alkyl; and/or

(C), deprotecting a protected derivative of compound of formula (I); and

optionally converting compounds of formula (I) prepared by any one of processes (A) to (C) into pharmaceutically acceptable derivatives thereof.

Suitable methods for the preparation of compounds of formula (I) and pharmaceutically acceptable derivatives thereof are disclosed in Scheme 1 that follows. In Scheme 1, R^1 to R^3 are as defined in formula (I) above unless otherwise stated; Hal is a halogen, such as Cl or Br; MTBE is methyl t-butyl ether; and alkyl is a straight or branched chain alkyl group, for example a methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl or t-butyl group.

Referring to Scheme 1, the treatment of compounds of formula (III) with an amine of formula (II) is conveniently carried out in a suitable solvent, such as acetonitrile or N-methylpyrrolidone, and at elevated temperature (e.g. from about 50°C to reflux). An excess of the amine may be used in place of the solvent.

Conveniently, the boronic acid coupling shown in Scheme 1 is carried out in a solvent, such as an ether (e.g. 1,2-dimethoxyethane); in the presence of a base, such as an inorganic base (e.g. sodium carbonate); and employing a palladium catalyst, such as tetrakis(triphenylphosphine)palladium(0).

Conveniently the oxidation shown in Scheme 1 is effected using a monopersulfate compound, such as potassium peroxymonosulfate (known as OxoneTM) and the reaction is carried out in a solvent, such as an aqueous

alcohol, (e.g. aqueous methanol), and at between -78°C and ambient temperature.


Referring to Scheme 1, the cyclisation of diones of formula (VI) to give the corresponding pyrimidines of formula (IV) is conveniently carried out employing a thiouronium salt such as a 2-methyl-2-thiopseudourea sulfate and under reflux.

5

It will be appreciated by those skilled in the art that certain of the procedures described in Scheme 1 for the preparation of compounds of formula (I) or intermediates thereto may not be applicable to some of the possible substituents.


10

Scheme 1



It will be further appreciated by those skilled in the art that it may be necessary or desirable to carry out the transformations described in Scheme 1 in a different order from that described, or to modify one or more of the transformations, to provide the desired compound of formula (I).

- 5 In one variation of Scheme 1, compounds of formula (III) wherein R^3 is C_{1-6} alkyl may be prepared by oxidising a disulphide of formula (IV)A:



- 10 under oxidation conditions described hereinabove. Disulphides of formula (IV)A may be prepared according to the general procedures of Scheme 1 by employing sulphide derivatives in place of the corresponding alkylsulphonyl compounds of formulae (VII) and (VIII).

- 15 It will be appreciated by those skilled in the art that compounds of formula (I) may be prepared by interconversion, utilising other compounds of formula (I) as precursors. Suitable interconversions, such as alkylations, are well known to those skilled in the art and are described in many standard organic chemistry texts, such as 'Advanced Organic Chemistry' by Jerry March, fourth edition (Wiley, 1992), incorporated herein by reference. For example, compounds of formula (I) wherein R^1 is C_{1-6} alkyl may be prepared by alkylating the corresponding compound of formula (I) wherein R^1 is H.

- 20 Acylation of compounds of formula (I) wherein R^3 is NH_2 to provide corresponding acylated benzenesulphonamide derivatives may be carried out by conventional means, for example by employing conventional acylating agents such as those described in 'Advanced Organic Chemistry', pp 417-424.

- 25 As will be appreciated by those skilled in the art it may be necessary or desirable at any stage in the synthesis of compounds of formula (I) to protect one or more sensitive groups in the molecule so as to prevent undesirable side reactions. The protecting groups used in the preparation of compounds of formula (I) may

be used in conventional manner. See, for example, those described in 'Protective Groups in Organic Synthesis' by Theodora W Green and Peter G M Wuts, second edition, (John Wiley and Sons, 1991), incorporated herein by reference, which also describes methods for the removal of such groups.

- 5 Amines of formula (II) are either known compounds or may be prepared by literature methods, such as those described in 'Comprehensive Organic Transformations: a guide to functional group preparations' by Richard Larock (VCH, 1989), incorporated herein by reference.

- 10 Thiouronium salts of formula (V) are either known compounds or may be prepared by literature methods, such as those described in A H Owens *et al*, Eur J Med Chem, 1988, 23(3), 295-300, incorporated herein by reference

Acetophenones of formula (VII) are either known compounds or may be prepared by conventional chemistry.

- 15 Boronic acids of formula (VIII) or derivatives thereof are either known compounds or may be prepared by literature methods, such as those described in EPA publication No. 533268; or R Miyaura *et al*, J Org Chem, 1995, 60, 7508-7510; each incorporated herein by reference.

- 20 4-Halo-6-trifluoromethylpyrimidines of formula (IX) are either known compounds or may be prepared by literature methods, such as those described in Japanese Patent no. 42014952 (Chem Abs ref CAN 68:105224), incorporated herein by reference.

- 25 Certain intermediates described above are novel compounds, and it is to be understood that all novel intermediates herein form further aspects of the present invention. Conveniently, compounds of the invention are isolated following work-up in the form of the free base. Pharmaceutically acceptable acid addition salts of the compounds of the invention may be prepared using conventional means.

Solvates (e.g. hydrates) of a compound of the invention may be formed during the work-up procedure of one of the aforementioned process steps.

The Intermediates and Examples that follow illustrate the invention but do not limit the invention in any way. All temperatures are in °C. Flash column chromatography was carried out using Merck 9385 silica. Solid Phase Extraction (SPE) chromatography was carried out using Varian Mega Bond Elut (Si) cartridges (Anachem) under 15mmHg vacuum with stepped gradient elution. Thin layer chromatography (Tlc) was carried out on silica plates. Autopurification was performed using a system comprising a Supelco ABZ+ column, 2xGilson 305 single piston pumps, a Gilson 155 Dual Wavelength UV detector, a Gilson 233XL autosampler/fraction collector, a Gilson 506c interface unit and a computer system operated via Gilson UniPoint software. The mobile phase was varied with time according to the following table wherein solvent A is 0.1% aqueous formic acid and solvent B is 95% acetonitrile.

Time (min)	%A	%B
0.01	70	30
1.45	70	30
20	40	60
30	40	60
30.02	0	100
54	0	100
54.02	70	30
56	70	30

In addition to those already defined, the following abbreviations are used: Me, methyl; Ac, acyl; DMSO, dimethylsulphoxide; TFA, trifluoroacetic acid; DME, dimethoxyethane; THF, tetrahydrofuran; DCM, dichloromethane; MTBE, methyl t-butyl ether; and NMP, N-methylpyrrolidone.

Intermediate 14,4,4-Trifluoro-1-[4-(methylthio)phenyl]butane-1,3-dione

To a solution of ethyl trifluoroacetate (7.95ml, 1.1eq) in MTBE (125ml) was added dropwise 25% sodium methoxide in methanol (16ml, 1.2eq).
5 4-Methylthioacetophenone (Aldrich, 10g, 0.06mol) was added portionwise and the mixture stirred at ambient temperature overnight. 2N Hydrochloric acid (40ml) was added cautiously and the organic phase separated, washed with brine and dried (Na₂SO₄) to give an orange solid. The orange solid was recrystallised from hot isopropanol to give the title compound as a yellow
10 crystalline solid (11.25g, 71%).

MH- 261

Intermediate 22-(Methylthio)-4-[4-(methylthio)phenyl]-6-(trifluoromethyl) pyrimidine

15 To a mixture of 4,4,4-trifluoro-1-[4-(methylthio)phenyl]butane-1,3-dione (5g) and 2-methyl-2-thiopseudourea sulfate (5.1g, 0.98eq) in acetic acid (100ml) was added sodium acetate (3g, 2eq) and heated under reflux for 8h. The mixture was concentrated *in vacuo* and water (100ml) added to give a solid, which was isolated by filtration to give the title compound as a yellow solid (5.8g,
20 quantitative).

MH+ 317

Intermediate32-(Methylthio)-4-[4-(methylthio)phenyl]-6-(trifluoromethyl) pyrimidine

25 A mixture of 4-chloro-2-methylthio-6-(trifluoromethyl)pyrimidine (ButtPark Ltd, 2.86g, 14.55mmol), 4-(methylthio)phenylboronic acid (Aldrich, 2.83g, 1.1eq), tetrakis(triphenylphosphine) palladium (0) (0.2g) and sodium carbonate (4.04g, 2.6eq) in DME (200ml) and water (100ml) was heated under reflux with stirring under N₂ for 24h. The reaction mixture was concentrated *in vacuo* and the
30 resultant mixture partitioned between ethyl acetate and water. The organic phase was separated, washed with water, dried (Na₂SO₄) and concentrated *in vacuo* to a purple solid. Purification by flash column chromatography with cyclohexane:ethyl acetate as (6:1) as eluant gave the title compound as a yellow crystalline solid (3.86g, 84%).

35 MH+ 317

TLC SiO₂ cyclohexane:ethyl acetate (3:1) R_f 0.75 uv₂₅₄

Intermediate 42-(Methylsulfonyl)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidine

To a solution of 2-(methylthio)-4-[4-(methylthio)phenyl]-6-(trifluoromethyl)pyrimidine (5.78g) in MeOH (500ml) was added a solution of OXONE™ (Aldrich, 56.23g, 5eq) in water (200ml). The mixture was stirred at ambient temperature overnight, concentrated *in vacuo* and the residue partitioned between water and ethyl acetate (2 x 100ml). The combined organic phases were dried and concentrated *in vacuo* to an off-white solid which was triturated with hot isopropanol to give the title compound as a white solid (5.6g, 80%).

MH+ 381

Tlc SiO₂ Ethyl acetate:cyclohexane (1:1) R_f 0.45Example 14-[4-(methylsulfonyl)phenyl]-N-tetrahydro-2H-pyran-4-yl-6-(trifluoromethyl)pyrimidin-2-amine

To a solution of 2-(methylsulfonyl)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidine (0.277g, 0.73mmol) in N-methylpyrrolidone (1.25ml) was added tetrahydro-2H-pyran-4-amine (0.147g, 2eq.), the mixture was stirred for 1 hour and then water (1.25ml) was added dropwise. This resulted in a precipitate being formed, which was collected by filtration, and dried *in vacuo* (0.258g). This material was then purified by autopurification to give the title compound as a colourless solid (0.116g, 40%).

MH+ 402

Example 24-[4-(Methylsulfonyl)phenyl]-N-methyl-N-tetrahydro-2H-pyran-4-yl-6-(trifluoromethyl)pyrimidin-2-amine

A solution of 4-[4-(methylsulfonyl)phenyl]-N-tetrahydro-2H-pyran-4-yl-6-(trifluoromethyl)pyrimidin-2-amine (0.05g) in dry dimethylformamide (2ml) was treated with sodium hydride (0.007g, 60% in mineral oil) and the mixture stirred at ambient temperature for 30 minutes. Iodomethane (0.01ml) was added and the mixture stirred overnight. The reaction mixture was concentrated *in vacuo* and the residue partitioned between dichloromethane (20ml) and water (20ml). The organic layer was purified by passing through a silica bond elute column

and eluting with dichloromethane. Concentration of the eluent gave the title compound as a yellow solid (0.031g).

LCMS r_t = 3.69 min

$m/z(MH^+) = 416$

5

The following examples were prepared by an analogous method to that for Example 2

Example 3

10 4-[4-(Methylsulfonyl)phenyl]-N-ethyl-N-tetrahydro-2H-pyran-4-yl-6-(trifluoromethyl)pyrimidin-2-amine

LCMS r_t = 3.68 min

$m/z(MH^+) = 430$

15 Example 4

4-[4-(Methylsulfonyl)phenyl]-N-butyl-N-tetrahydro-2H-pyran-4-yl-6-(trifluoromethyl)pyrimidin-2-amine

LCMS r_t = 3.82

$m/z(MH^+) = 458$

20

Biological Data

Inhibitory activity against human COX-1 and COX-2 was assessed in COS cells which had been stably transfected with cDNA for human COX-1 and human COX-2. 24 Hours prior to experiment, COS cells were transferred from the 175cm² flasks in which they were grown, onto 24-well cell culture plates using the following procedure. The incubation medium (Dulbecco's modified eagles medium (DMEM) supplemented with heat-inactivated foetal calf serum (10%v/v), penicillin (100 IU/ml), streptomycin (100µg/ml) and geneticin (600µg/ml)) was removed from a flask of confluent cells (1 flask at confluency contains approximately 1x10⁷ cells). 5ml of phosphate buffered saline (PBS) was added to the flask to wash the cells. Having discarded the PBS, cells were then incubated with 5ml trypsin for 5 minutes in an incubator (37°). The flask was then removed from the incubator and 5ml of fresh incubation medium was added. The contents of the flask was transferred to a 250ml sterile container and the volume of incubation medium subsequently made up to 100ml. 1ml cell suspension was pipetted into each well of 4x24-well cell culture plates. The

35

plates were then placed in an incubator (37°C, 95% air/5% CO₂) overnight. If more than 1 flask of cells were required, the cells from the individual flasks were combined before being dispensed into the 24-well plates.


5 Following the overnight incubation, the incubation medium was completely removed from the 24-well cell culture plates and replaced with 250µl fresh DMEM (37°C). The test compounds were made up to 250x the required test concentration in DMSO and were added to the wells in a volume of 1µl. Plates were then mixed gently by swirling and then placed in an incubator for 1 hour (37°C, 95% air/5% CO₂). Following the incubation period, 10µl of arachidonic acid (750µM) was added to each well to give a final arachidonic acid concentration of 30µM. Plates were then incubated for a further 10 minutes, after which the incubation medium was removed from each well of the plates and stored at -20°C, prior to determination of prostaglandin E₂ (PGE₂) levels using enzyme immunoassay. The inhibitory potency of the test compound was expressed as an IC₅₀ value, which is defined as the concentration of the compound required to inhibit the PGE₂ release from the cells by 50%. The selectivity ratio of inhibition of COX-1 versus COX-2 was calculated by comparing respective IC₅₀ values.

15 The following IC₅₀ values for inhibition of COX-2 and COX-1 were obtained for compounds of the invention:

Example No.	COX-2: IC ₅₀ (nM)	COX-1: IC ₅₀ (nM)
1	18	>91,000
2	16.8	60357
3	24.9	69710
4	143.3	71815

CLAIMS


1. A compound of formula (I)



- 5 and pharmaceutically acceptable derivatives thereof, in which:

R^1 is H or C_{1-6} alkyl;

R^2 is




) defines the point of attachment of the ring; and

R^3 is C_{1-6} alkyl or NH_2 .

10


2. A compound as claimed in claim 1 wherein R^1 is H.
3. A compound as claimed in claim 1 or 2 wherein R^1 is C_{1-2} alkyl.
- 15 4. A compound as claimed in any of claims 1 to 3 wherein R^2 is



5. A compound as claimed in any of claims 1 to 4 wherein R^3 is C_{1-6} alkyl.


20

6. A compound as claimed in any of claims 1 to 5 wherein R^1 is H; R^2 is



and R^3 is methyl.

7. A compound as claimed in any of claims 1 to 5 wherein R^1 is C_{1-2} alkyl; R^2 is



5 and R^3 is methyl.

8. A compound of formula (I) as defined in claim 1 selected from:

4-[4-(methylsulfonyl)phenyl]-N-tetrahydro-2H-pyran-4-yl-6-(trifluoromethyl)pyrimidin-2-amine;

10 4-[4-(methylsulfonyl)phenyl]-N-methyl-N-tetrahydro-2H-pyran-4-yl-6-(trifluoromethyl)pyrimidin-2-amine;

4-[4-(methylsulfonyl)phenyl]-N-ethyl-N-tetrahydro-2H-pyran-4-yl-6-(trifluoromethyl)pyrimidin-2-amine;


and pharmaceutically acceptable derivatives thereof.

15

9. A process for the preparation of a compound of formula (I) and pharmaceutically acceptable derivatives thereof as defined in any one of claims 1 to 8, which comprises:

(A), reacting an amine HNR^1R^2 of formula (II) or a protected derivative thereof with a compound of formula (III)

20



(III)

or a protected derivative thereof; or

(B), interconverting of a compound of formula (I) into another compound of formula (I); in particular, for a compound of formula (I) in which R^1 is H, alkylation thereof to give a compound of formula (I) in which R^1 is C_{1-6} alkyl; and/or

25

(C), deprotecting a protected derivative of compound of formula (I); and

optionally converting compounds of formula (I) prepared by any one of processes (A) to (C) into pharmaceutically acceptable derivatives thereof.

- 5 10. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof as defined in any one of claims 1 to 8 in admixture with one or more physiologically acceptable carriers or excipients.
- 10 11. A compound of formula (I) or a pharmaceutically acceptable derivative thereof as defined in any one of claims 1 to 8 for use in human or veterinary medicine.
- 15 12. A method of treating a human or animal subject suffering from a condition which is mediated by selective inhibition of COX-2 which comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof as defined in any one of claims 1 to 8.
- 20 13. A method of treating a human or animal subject suffering from an inflammatory disorder, which method comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof as defined in any one of claims 1 to 8.
- 25 14. The use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof as defined in any one of claims 1 to 8 for the manufacture of a therapeutic agent for the treatment of a condition which is mediated by selective inhibition of COX-2.
- 30 15. The use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof as defined in any one of claims 1 to 8 for the manufacture of a therapeutic agent for the treatment of an inflammatory disorder.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 01/03935

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D405/12 A61K31/505 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, BEILSTEIN Data, CHEM ABS Data, EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, Y	WO 01 58881 A (PAYNE JEREMY JOHN ; PEGG NEIL ANTHONY (GB); MAYLOR ALAN (GB); GLAXO) 16 August 2001 (2001-08-16) the whole document ---	1-15
P, Y	WO 01 38311 A (HARTLEY CHARLES DAVID ; PAYNE JEREMY JOHN (GB); PEGG NEIL ANTHONY ()) 31 May 2001 (2001-05-31) the whole document ---	1-15
A	WO 98 03484 A (GAUTHIER JACQUES YVES ; MERCK FROSST CANADA INC (CA); DUBE DANIEL ()) 29 January 1998 (1998-01-29) the whole document --- -/--	1-15

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

22 October 2001

Date of mailing of the international search report

26/10/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Scruton-Evans, I

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 01/03935

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 24782 A (AMGEN INC ;MANTLO NATHAN B (US); SPOHR ULRIKE D (US); MALONE MICHA) 11 June 1998 (1998-06-11) see definition of R11 ---	1-15
A	US 6 020 343 A (GAUTHIER JACQUES YVES ET AL) 1 February 2000 (2000-02-01) the whole document -----	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 01/03935

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0158881	A	16-08-2001	WO 0158881 A1	16-08-2001
WO 0138311	A	31-05-2001	AU 2508401 A	04-06-2001
			WO 0138311 A2	31-05-2001
WO 9803484	A	29-01-1998	AU 723179 B2	17-08-2000
			AU 3331997 A	10-02-1998
			BG 103179 A	30-11-1999
			CA 2260016 A1	29-01-1998
			WO 9803484 A1	29-01-1998
			CZ 9900130 A3	16-06-1999
			EE 9900018 A	16-08-1999
			EP 0912518 A1	06-05-1999
			HR 970389 A1	30-06-1998
			JP 11514008 T	30-11-1999
			NO 990191 A	16-03-1999
			PL 330995 A1	21-06-1999
			SK 3699 A3	10-12-1999
			TR 9900046 T2	21-04-1999
			BR 9710372 A	17-08-1999
			HU 9903974 A2	28-03-2000
			US 6001843 A	14-12-1999
			US 6071936 A	06-06-2000
			US 5861419 A	19-01-1999
WO 9824782	A	11-06-1998	AU 735901 B2	19-07-2001
			AU 5525498 A	29-06-1998
			AU 733877 B2	31-05-2001
			AU 6012098 A	29-06-1998
			BG 103512 A	31-07-2000
			BG 103521 A	31-07-2000
			BR 9713850 A	29-02-2000
			BR 9713863 A	14-03-2000
			CN 1246857 A	08-03-2000
			CN 1246858 A	08-03-2000
			CZ 9902015 A3	17-11-1999
			CZ 9902016 A3	17-11-1999
			EP 0948496 A2	13-10-1999
			EP 0948497 A2	13-10-1999
			HU 0001140 A2	28-04-2001
			HU 0001698 A2	28-04-2001
			WO 9824782 A2	11-06-1998
			WO 9824780 A2	11-06-1998
			US 6096753 A	01-08-2000
US 6020343	A	01-02-2000	US 6169188 B1	02-01-2001
			US 5981576 A	09-11-1999
			AU 703871 B2	01-04-1999
			AU 7123696 A	07-05-1997
			BG 102425 A	30-06-1999
			BR 9611015 A	14-09-1999
			CA 2233178 A1	24-04-1997
			WO 9714691 A1	24-04-1997
			CN 1200119 A	25-11-1998
			CZ 9801101 A3	16-09-1998
			EE 9800080 A	15-10-1998
			EP 0863891 A1	16-09-1998
			HR 960458 A1	30-04-1998

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/GB 01/03935

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 6020343	A	HU 9802506 A2	28-05-1999
		JP 11500146 T	06-01-1999
		JP 2001199954 A	24-07-2001
		NO 981628 A	27-05-1998
		PL 326203 A1	31-08-1998
		SK 45098 A3	02-12-1998
		TR 9800585 T2	21-07-1998
		TW 426679 B	21-03-2001
		ZA 9608609 A	14-04-1997
<hr/>			